The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study
Open accessAbstract
BACKGROUND: Volanesorsen, an investigational inhibitor of apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by marked chylomicronemia leading to a spectrum of symptoms, including recurrent abdominal pain and episodes of potentially fatal acute pancreatitis (AP). OBJECTIVE: To determine the effect of volanesorsen on burden of disease on patients with FCS Methods: ReFOCUS was a retrospective global web-based survey open to patients with FCS who received volanesorsen for ≥3 months in an open-label extension study. The survey included questions about patients' experiences before and after volanesorsen treatment. RESULTS: Twenty-two respondents had received volanesorsen for a median of 222 days. Volanesorsen significantly reduced the number of symptoms per patient across physical, emotional, and cognitive domains. Significant reductions from baseline were reported for steatorrhea, pancreatic pain, and constant worry about an attack of pain/AP. Respondents reported that volanesorsen improved overall management of symptoms and reduced interference of FCS with work/school responsibilities. Reductions in the negative impact of FCS on personal, social, and professional life were also reported. CONCLUSIONS: Treatment with volanesorsen has the potential to reduce disease burden in patients with FCS through modulation of multiple symptom domains.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Quality of life analysis showed reduction of pancreatitis-related symptoms.
“Quality of life analysis showed reduction of pancreatitis-related symptoms.76”
From Clinical review on triglycerides (2020) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549 · see citing works
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491 · see citing works
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439 · see citing works
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377 · see citing works
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356 · see citing works
Nawaz, H., Koutroumpakis, E., Easler, J., Slivka, A., Whitcomb, D. C., Singh, V. P., Yadav, D., & Papachristou, G. I. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.261 · Cited by 296 · see citing works
Hypertriglyceridemia and acute pancreatitis
Murphy, M. J., Sheng, X., MacDonald, T. M., & Wei, L. (2013) · JAMA Internal Medicine · doi:10.1001/2013.jamainternmed.477 · Cited by 172 · see citing works
Diagnostic algorithm for familial chylomicronemia syndrome
Stroes, E., Moulin, P., Parhofer, K. G., Rebours, V., Löhr, J.-M., & Averna, M. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2016.10.002 · Cited by 130 · see citing works
Gaudet, D., de Wal, J., Tremblay, K., Déry, S., van Deventer, S. J. H., Freidig, A. P., Brisson, D., & Méthot, J. (2010) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2010.03.004 · Cited by 122 · see citing works
Relationship between the exocrine and endocrine pancreas after acute pancreatitis
Das, S. L. M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.17196 · Cited by 116 · see citing works
Structure and Dynamics of Human Apolipoprotein CIII
Gangabadage, C. S., Zdunek, J., Tessari, M., Nilsson, S., Olivecrona, G., & Wijmenga, S. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800756200 · Cited by 88 · see citing works
The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study
Davidson, M., Stevenson, M., Hsieh, A., Ahmad, Z., Crowson, C., & Witztum, J. L. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1311786 · Cited by 54 · see citing works
Self-citationSevere Hypertriglyceridemia Induced Pancreatitis in Pregnancy
Gupta, N., Ahmed, S., Shaffer, L., Cavens, P., & Blankstein, J. (2014) · Case Reports in Obstetrics and Gynecology · doi:10.1155/2014/485493 · Cited by 49 · see citing works
Gaudet, D., DIGENIO, A. G., Alexander, V. J., Arca, M., Jones, A. F., Stroes, E. S. G., Bergeron, J., Civeira, F., Hemphill, L., Blom, D. J., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.04.071 · Cited by 44 · see citing works
Self-citationWatts, G. F., MORTON, K., Jackson, P., & Lewis, B. (1992) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1992.tb14481.x · Cited by 28 · see citing works
Acute pancreatitis associated with hypertriglyceridemia: a life-threatening complication
Kayataş, S., Eser, M., Çam, Ç., Çöğendez, E., & Güzin, K. (2009) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-009-1183-0 · Cited by 28 · see citing works
Medical resource use and costs associated with chylomicronemia
Gaudet, D., Signorovitch, J., Swallow, E., Fan, L., Tremblay, K., Brisson, D., Meyers, C. D., & Gruenberger, J.-B. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.779277 · Cited by 25 · see citing works
Editorial commentary: Dietary management of familial chylomicronemia syndrome
Williams, L., & Wilson, D. P. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.023 · Cited by 24 · see citing works
Gaudet, D., DIGENIO, A. G., Alexander, V., Arca, M., Jones, A. F., Stroes, E. S. G., Bergeron, J., Civeira, F., Hemphill, L., Blom, D. J., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.059 · Cited by 22 · see citing works
Self-citationThe American Society for Preventive Cardiology Abstracts
(2017) · Clinical Cardiology · doi:10.1002/clc.22777 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med. 1992;37:249-273.
- Davidson M, Stevenson M, Hsieh A, et al. Examining the high disease burden and impact on quality of life in familial chylomi- cronemia syndrome -results from the IN-FOCUS study. Clin Cardiol. 2017;40:4-15.
Cited by
Sorted by citations
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544 · see citing works
Volanesorsen: First Global Approval
Paik, J., & Duggan, S. T. (2019) · Drugs · doi:10.1007/s40265-019-01168-z · Cited by 209 · see citing works
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171 · see citing works
A new dawn for managing dyslipidemias: The era of rna-based therapies
Macchi, C., Sirtori, C. R., Corsini, A., Santos, R. D., Watts, G. F., & Ruscica, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104413 · Cited by 94 · see citing works
Esan, O., & Wierzbicki, A. S. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 80 · see citing works
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 62 · see citing works
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
Gareri, C., Polimeni, A., Giordano, S. A., Tammè, L., Curcio, A., & Indolfi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133884 · Cited by 59 · see citing works
Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
Fogacci, F., Norata, G. D., Toth, P. P., Arca, M., & Cicero, A. F. G. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00836-w · Cited by 41 · see citing works
Self-citationApolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38 · see citing works
Calcaterra, I. L., Lupoli, R., Minno, A. D., & Minno, M. N. D. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13841 · Cited by 38 · see citing works
The biochemical and genetic diagnosis of lipid disorders
Schaefer, E. J., Geller, A. S., & Endress, G. A. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000590 · Cited by 37 · see citing works
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 38 · see citing works
Safety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37 · see citing works
Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia
Kolovou, G., Kolovou, V., & Katsiki, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040982 · Cited by 33 · see citing works
Volanesorsen for treatment of familial chylomicronemia syndrome
Lazarte, J., & Hegele, R. A. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955348 · Cited by 25 · see citing works
D’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 24 · see citing works
Self-citationEmerging drugs for the treatment of hypercholesterolemia
Bove, M., Cicero, A. F. G., & Borghi, C. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591372 · Cited by 21 · see citing works
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 19 · see citing works
Present and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 21 · see citing works
Jia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 18 · see citing works
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18 · see citing works
Etiology and emerging treatments for familial chylomicronemia syndrome
Spagnuolo, C. M., & Hegele, R. A. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2365787 · Cited by 17 · see citing works
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17 · see citing works
Recent Apolipoprotein CIII trials
Tramontano, D., Bini, S., D’Erasmo, L., & Arca, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000849 · Cited by 14 · see citing works
Self-citationAfanasieva, O. I., Владиславович, Е. М., & Pokrovsky, S. N. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-99-109 · Cited by 13 · see citing works
Fox, R. S., Peipert, J. D., Vera‐Llonch, M., Phillips, G. A., & Cella, D. F. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1748011 · Cited by 12 · see citing works
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0771-8_5 · Cited by 10 · see citing works
Monticelli, M., Francisco, R., Brasil, S., Marques‐da‐Silva, D., Rijoff, T., Pascoal, C., Jaeken, J., Videira, P. A., & Ferreira, V. D. R. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02460-0 · Cited by 9 · see citing works
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10 · see citing works
Navigating Lipodystrophy: Insights from Laminopathies and Beyond
Krüger, P., Hartinger, R., & Djabali, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158020 · Cited by 8 · see citing works
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
Kosmas, C. E., Sourlas, A., Silverio, D., Montan, P. D., & Guzman, E. (2019) · World Journal of Cardiology · doi:10.4330/wjc.v11.i11.256 · Cited by 8 · see citing works
Watts, L. M., Karwatowska‐Prokopczuk, E., Hurh, E., Alexander, V. J., Balogh, K., O'Dea, L. S. L., Geary, R. S., & Tsimikas, S. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0837 · Cited by 7 · see citing works
Self-citationDrug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen
Gesner, M., & Frishman, W. H. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000468 · Cited by 5 · see citing works
Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28
Kaiser, K., Fox, R. S., Perschon, C. R., Vera‐Llonch, M., Alonso, J., Cubells, L., & Cella, D. F. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03266-0 · Cited by 5 · see citing works
Posicionamento Brasileiro sobre Síndrome da Quilomicronemia Familiar – 2023
Izar, M. C. D. O., Santos, R. D., Assad, M. H. V., Chagas, A. C. P., Toledo, A. D. O., Nogueira, A. C. C., Souto, A. C. C. F., Lottenberg, A. M., Chacra, A. P. M., Ferreira, C. E. D. S., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230203 · Cited by 7 · see citing works
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4 · see citing works
Real life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia
Román-Gonzaléz, A., Castellanos, A., Perdomo, D. F. S., Peña, C. A. C., Vargas, J. J., Mendivil, C. O., & Gutiérrez-Restrepo, J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.203 · Cited by 2 · see citing works
Dey, H., Agarwal, V., Ali, M. N., Upadhyay, A., Shafieq, S., Dixit, B., Tomar, S., & Tarannum, M. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i4.6533 · Cited by 1 · see citing works
Meghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1 · see citing works
Síndrome de Quilomicronemia Familiar: Algoritmo Diagnóstico
Colaco, I. B., Araújo, F., Aguiar, P., Cruz, D., Bourbon, M., Duarte, J. S., & Veríssimo, M. T. (2021) · Medicina Interna · doi:10.24950/rspmi.r.92.4.2021 · Cited by 1 · see citing works
Pediatric Primary and Secondary Hyperlipidemias
Levy, E. H., Marcil, V., & DELVIN, E. E. (2018) · Encyclopedia of Gastroenterology · doi:10.1016/b978-0-12-801238-3.65911-1
Síndrome de quilomicronemia familiar: uma atualização sobre tratamento farmacológico
Santana, R. R., & Andrade, B. S. (2023) · Revista Científica Eletrônica do Conselho Regional de Farmácia da Bahia · doi:10.4322/rce-crf-ba.e02022302
张, 卓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451662
Monticelli, M., Francisco, R., Brasil, S., Marques‐da‐Silva, D., Rijoff, T., Pascoal, C., Jaeken, J., Videira, P. A., & Ferreira, V. D. R. (2022) · Figshare · doi:10.6084/m9.figshare.20408670
Monticelli, M., Francisco, R., Brasil, S., Marques‐da‐Silva, D., Rijoff, T., Pascoal, C., Jaeken, J., Videira, P. A., & Ferreira, V. D. R. (2022) · Figshare · doi:10.6084/m9.figshare.20408667
Monticelli, M., Francisco, R., Brasil, S., Marques‐da‐Silva, D., Rijoff, T., Pascoal, C., Jaeken, J., Videira, P. A., & Ferreira, V. D. R. (2022) · Figshare · doi:10.6084/m9.figshare.20408661
Monticelli, M., Francisco, R., Brasil, S., Marques‐da‐Silva, D., Rijoff, T., Pascoal, C., Jaeken, J., Videira, P. A., & Ferreira, V. D. R. (2022) · Figshare · doi:10.6084/m9.figshare.20408697
Monticelli, M., Francisco, R., Brasil, S., Marques‐da‐Silva, D., Rijoff, T., Pascoal, C., Jaeken, J., Videira, P. A., & Ferreira, V. D. R. (2022) · Figshare · doi:10.6084/m9.figshare.20408664
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_5
- Authors
- Arca, M., Hsieh, A., Soran, H., Rosenblit, P., O’Dea, L., & Stevenson, M.
- Affiliations
- Sapienza University of Rome (IT)
- Akcea Therapeutics, Cambridge, MA, USA
- Manchester University NHS Foundation Trust (GB)
- University of California, Irvine (US)
- Corresponding author
- Stevenson, Michael
- Venue
- Expert Review of Cardiovascular Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-06-22
- Volume
- 16
- Issue
- 7
- Pages
- 537-546
- ISSN
- 1477-9072 (ISSN-L)
- 1744-8344
- OpenAlex
- W2808484157
- Cited by
- 49
- References
- 20
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 3 · 2022: 13 · 2021: 3 · 2020: 8 · 2019: 10 · 2018: 3 · 2017: 1
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Expert Review of Cardiovascular Therapy (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Funders
- Akcea Therapeutics, Inc (Not applicable)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- volanesorsen, familial chylomicronemia syndrome, disease burden, apolipoprotein C-III, acute pancreatitis, steatorrhea, symptom management, quality of life, patient-reported outcomes, hypertriglyceridemia
- MeSH terms
- Adult, Aged, Female, Humans, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Retrospective Studies, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
